ATH 25.0% 0.5¢ alterity therapeutics limited

Yes, Reach was about the safety and tolerability of PBT2, but it...

  1. 220 Posts.
    lightbulb Created with Sketch. 89
    Yes, Reach was about the safety and tolerability of PBT2, but it was also about its effect on amyloid deposition in the brain. Participants were to undergo brain scans to measure PBT2’s effect on amyloid deposits in the brain and effects on increasing brain activity. Cognition effects were being measured using scientifically validated tests (TMTB being one) that measure the type of cognitive problems experienced by prodromal and early Alzheimer’s patients. I wasn't aware that unlike the original 12 months the extension only concentrated on safety.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $27.94K 6.050M

Buyers (Bids)

No. Vol. Price($)
46 57663299 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 56205001 43
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 20524121
Last updated 15.46pm 29/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.